TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of PF-06873600 in People With Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Have a diagnosis of Hormone Receptor Positive (HR+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-) breast cancer~  • Prior combined CDK 4/6 inhibitor and endocrine therapy and 1 or 2 prior lines of chemotherapy~* Have a diagnosis of metastatic triple negative breast cancer (TNBC)~  • Up to 1-2 prior lines of chemotherapy~* Have a diagnosis of advanced platinum resistant epithelial ovarian cancer (EOC)/fallopian tube cancer/primary peritoneal cancer (PPC)~  • Up to 2-3 prior lines of therapy~* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1~* Measurable disease or non-measurable disease and refractory to or intolerant of existing therapies (Part 1)~* Measurable disease as defined by RECIST 1.1 is required (Part 1B and Part 2 only)~Exclusion Criteria:~* Known active uncontrolled or symptomatic Central Nervous System (CNS) metastases~* Other active malignancy within 3 years prior to randomization, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ~* Major surgery or radiation within 4 weeks prior to study entry~* Last anti-cancer treatment within 2 weeks prior to study entry~* Participation in other studies involving investigational drug(s) within 4 weeks prior to study entry~* Pregnant or breastfeeding female patients~* Active inflammatory gastrointestinal (GI) disease, known diverticular disease or previous gastric resection or lap band surgery including impairment of gastro intestinal function or GI disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dose Escalation (Type: EXPERIMENTAL): Single Agent Dose Escalation
- Dose Finding Endocrine Therapy 1 Combination (Type: EXPERIMENTAL): Part 1B PF-06873600 plus Endocrine Therapy 1
- Dose Finding Endocrine Therapy 2 Combination (Type: EXPERIMENTAL): Part 1B PF-06873600 plus Endocrine Therapy 2
- Dose Expansion Arm A (Type: EXPERIMENTAL): PF-06873600 as a Single Agent
- Dose Expansion Arm B (Type: EXPERIMENTAL): PF-06873600 as a Single Agent in Various Tumor Types
- Dose Expansion Arm C (Type: EXPERIMENTAL): PF-06873600 in Combination with Endocrine Therapy 1
- Dose Expansion Arm D (Type: EXPERIMENTAL): PF-06873600 in Combination with Endocrine Therapy 1
- Dose Expansion Arm E (Type: EXPERIMENTAL): PF-06873600 in Combination with Endocrine Therapy 2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Towards Individualized Deep Brain Stimulation Treatment of Chronic Neuropathic Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~General inclusion criteria (case and control):~* No gender criteria~* Age \> 25 years.~* Legal competency.~* Ability to comply with the proposed protocol schedule.~* Stability of chronic medical diseases.~* A negative validated pregnancy test for fertile female participants prior to project enrolment.~* Use of validated anti-conception for fertile female participants~Case-specific inclusion criteria:~* Well-defined neuropathic pain \[21\].~* Chronic and stable pain condition. Numerical Rating Scale score \> 5.~* Documented resistance to, or poor tolerance of pharmacological treatments. Unless contraindicated, the treatment must have included opiate derivatives, tri-cyclic antidepressants and anti-epileptic drugs.~Exclusion Criteria:~General exclusion criteria:~* Pregnancy or nursing.~* Cognitive impairment.~* Alcohol or drug abuse~* Severe psychiatric disorders.~* Allergies towards compounds used in the trial, such as PET tracers, Capsaicin, etc. Other significant medical allergies.~* Severe medical disorders~* Neurodegenerative disorders~* Severe cerebrovascular diseases and risk-factors, malignant hypertension, vascular abnormalities.~* Prior intracranial surgery~* Cardiac pacemaker or other implanted electronic medical devices~* Coagulopathy (excl. drug induced)~* Structural brain abnormalities~* Epilepsy or prior isolated seizure.~* Severe obesity~* Severe claustrophobia~* Magnetic metallic implants~* Other conditions that may contraindicate deep brain stimulation surgery, full anesthesia, transcranial magnetic stimulation, PET/CT imaging (specifically the use of carfentanil) or magnetic resonance imaging. This will be evaluated according to specific investigational product specifications and clinical guidelines.~Control specific exclusion criteria:~- Chronic pain syndrome

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Sham-DBS (Type: SHAM_COMPARATOR): Only patients. Inactive deep brain stimulation for the initial three months following implantation.
- Active DBS (Type: ACTIVE_COMPARATOR): Only patients. Active deep brain stimulation for the initial three months following surgery.
- TMS and PET imaging (Type: EXPERIMENTAL): This experiment includes all participants (cases and controls). Each subject will undergo both active and sham stimulation (cross-over) with Cervel Neurotech Multi-coil TMS and related test/re-test PET imaging with 11C-Carfentanil. Only patients will proceed into deep brain stimulation experiments.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of the Combined Ablation Procedure to Treat Paroxysmal Atrial Fibrillation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years; \< 80 years~* Left atrium less than or equal to 6.5 cm (TTE)~* Symptomatic paroxysmal AF~* Provided written informed consent~* Refractory to at least one AAD (class I, II, III or IV)~Exclusion Criteria:~* Patients requiring concomitant surgery~* Left ventricular ejection fraction \< 30%~* Pregnant or planning to become pregnant during study~* Co-morbid medical conditions that limit one year life expectancy~* Measured left ventricular wall thickness \> 1.5 cm~* History of coagulopathy~* Previous cardiac surgery~* Right ventricular outflow tract obstruction~* History of pericarditis~* Previous cerebrovascular accident (CVA), excluding fully resolved TIA~* Patients who have severe chronic obstructive pulmonary disease (COPD)~* Patients who have an active infection or sepsis~* Patients who have uncorrected reversible cause(s) of AF~* Patients who are contraindicated for anticoagulants~* Patients who are being treated for arrhythmias other than AF~* Patients who have had any previous AF or left atrial catheter ablation~* Current participation in another clinical investigation of a medical device or a drug, or recent participation in such a study within 30 days prior to study enrollment.~* Not competent to legally represent him or herself (e.g., requires a guardian or caretaker as a legal representative).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Numeris-AF Guided Coagulation System (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Controlled Trial of Vaginal Progesterone in Women With Threatened Preterm Labor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women with symptomatic premature contractions successfully arrested for at least 12 hours with tocolytics.~* Women with symptoms suggestive of early preterm labor whose contractions resolve without tocolysis but are fetal fibronectin positive.~* Gestational age 23(+0)-32(+6) weeks.~* Consent to taking part in the study.~Exclusion Criteria:~* Placenta previa~* Preterm premature rupture of membranes at presentation~* Pre-existing hypertension will be excluded in order to reduce the likelihood of iatrogenic preterm delivery within the study women~* Known major fetal anomaly detected on ultrasound~* Multiple pregnancy~* Maternal seizure disorder~* Active or history of thromboembolic disease~* Maternal liver disease~* Known or suspected breast malignancy or pathology~* Known or suspected progesterone-dependent neoplasia~* Plans to move to another city during pregnancy~* Previous participation in a progesterone trial during this pregnancy~* Known sensitivity to progesterone

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Vaginal progesterone (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Epidural and Intravenous Patient-Controlled Analgesia Following Lumbar Spinal Fusion Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult subjects aged 18 years or older~* Scheduled for elective posterior lumbar spinal fusion surgery between 1 and 3 levels~Exclusion Criteria:~* Baseline cognitive deficits sufficient to make objective pain self-assessments unreliable in the estimation of the Study Investigators.~* Immunocompromised subject~* Coagulopathy~* Severe liver and renal dysfunction~* Preoperative neurological deficits~* The dura damage during surgery~* Inability to follow directions or comprehend the English language.~* Females who are pregnant as determined by positive pregnancy test on or before the day of surgery.~* Prisoners.~* Patient refusal to provide informed consent.~* Allergy to amide local anesthetics (lidocaine, bupivacaine, ropivacaine) or opioid (fentanyl) allergy if patient assigned epidural analgesia.~* Hydromorphone allergy if patient assigned IV PCA

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Patient-Controlled Epidural Analgesia (Type: EXPERIMENTAL): Bupivacaine and fentanyl infusion via Continuous Lumbar Epidural Analgesia during postoperative 72 hours
- Intravenous patient-controlled analgesia (Type: SHAM_COMPARATOR): Postoperative intravenous patient-controlled analgesia (IV PCA) with Hydromorphone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Application of MACS and Time-lapse Technology in Good-prognosis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* \<38 years~* \>10 follicles with a diameter of ≥10 mm the day before the follicular puncture~Exclusion Criteria:~* Patients subject to preimplantation genetic diagnosis treatments

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 38 Years
- Healthy Volunteers: f

Study Arms:
- NO MACS + Time-lapse technology (Type: ACTIVE_COMPARATOR): The sperm capacitation will be performed through a density gradient. This sperm will be used in the IVF/ICSI treatment of the patient and the embryos obtained will be cultured using time-lapse technology (Embryoscope).
- MACS + time-lapse technology (Type: EXPERIMENTAL): The sperm capacitation will be performed through a density gradient. After that, it will be subjected to the MACS technique in order to select the non-apoptotic spermatozoids. This sperm will be used in the IVF/ICSI treatment of the patient and the embryos obtained will be cultured using time-lapse technology (Embryoscope).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Certolizumab Pegol for Treatment of Adult Greek Patients With Moderate to Severe Crohn's Disease Who Failed Infliximab

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~• Adult men and women with Crohn's disease previously responsive to infliximab who became non-responsive or intolerant~Exclusion Criteria:~* Symptomatic obstructive intestinal strictures~* Bowel resection within 4 weeks~* Current total parenteral nutrition~* Short bowel syndrome~* Concomitant disease or pathological condition that could interfere with Crohn's disease or to be harmful for the well being of the patient.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Certolizumab pegol (Type: EXPERIMENTAL): certolizumab pegol 400 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility Study on LITT for Medical Refractory Epilepsy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Relevant Inclusion Criteria are listed below~* Diagnosis of unilateral medial temporal lobe epilepsy (MTLE) confirmed clinically and with either (1) ictal scalp recording and MRI evidence of mesial temporal sclerosis or (2) intracranial ictal onset consistent with hippocampal origin~* Averages 1 or more complex partial seizures or secondary generalized seizures compatible with MTLE per month~* On stable antiepileptic medications~* Meets the criteria for a medial temporal lobe resection and is a candidate for LITT~* 18 years or older at the time of consent~Relevant Exclusion Criteria are listed below~* Previous diagnosis of psychogenic/non-epileptic seizures~* Previous diagnosis of primary generalized seizures~* IQ less than 70~* Subject has a MRI-incompatible implanted electronic device or any metallic prosthesis or implant for which brain MRI is contraindicated

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NeuroBlate LITT Treatment (Type: OTHER): This is a single arm study. All eligible study subjects will undergo LITT with the NeuroBlate System.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Histamine and Bone Pain Association in Participants With Breast Cancer Metastatic in the Bone

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Breast cancer patients with radiographic evidence of bone metastases (by plain film, computed tomography \[CT\], magnetic resonance imaging \[MRI\], positron emission tomography \[PET\] or bone scan) within 8 weeks of registration~  * Weight bearing sites: pelvis (excluding pubis), femur, sacrum and/or sacroiliac joints, tibia, up to 5 consecutive cervical, thoracic or lumbar vertebral bodies, lumbosacral spine~ * Non-weight bearing sites: up to 3 consecutive ribs, humerus, fibula, radius +/- ulna, clavicle, sternum, scapula, pubis~* Patients with and without pain related to the radiographically documented metastases are eligible for study~* Ability to understand and the willingness to sign an Institutional Review Board (IRB)-approved informed consent document~Exclusion Criteria:~* Pregnant women will be excluded

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ancillary-Correlative (biospecimen collection) (Type: None): Participants undergo collection of blood samples for histamine level analysis via ELISA.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Temozolomide During and After Radiation Therapy in Treating Patients Who Have Undergone Previous Surgery and Placement of Gliadel Wafers for Newly Diagnosed Glioblastoma Multiforme

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed supratentorial grade IV astrocytoma (glioblastoma multiforme)~* Underwent gross total resection within the past 6 weeks~  * Postoperative contrast-enhancing tumor extends ≤ 1 cm from the margin of the surgical cavity~ * 6-8 polifeprosan 20 with carmustine implants (Gliadel® wafers) were placed in the surgical resection cavity at time of surgery~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* Karnofsky 60-100%~Life expectancy~* Not specified~Hematopoietic~* Absolute neutrophil count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~Hepatic~* Bilirubin ≤ 1.5 mg/dL~* Transaminases ≤ 4 times upper limit of normal~Renal~* Creatinine ≤ 1.7 mg/dL~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No known hypersensitivity reaction to temozolomide~* No other malignancy within the past 5 years except curatively treated carcinoma in situ or basal cell skin cancer~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No prior immunotherapy for the brain tumor~* No prior biologic agents (e.g., immunotoxins, immunoconjugates, antisense agents, peptide-receptor agonists, interferons, interleukins, tumor-infiltrating lymphocyte therapy, lymphokine-activated killer cell therapy, or gene therapy) for the brain tumor~Chemotherapy~* See Disease Characteristics~* No other prior chemotherapy for the brain tumor~Endocrine therapy~* No prior hormonal therapy for the brain tumor~* Prior glucocorticoid therapy allowed~Radiotherapy~* No prior radiotherapy for the brain tumor~Surgery~* See Disease Characteristics

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Trial for Pain Management in Low-grade Subarachnoid Hemorrhage

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age\>18-75~* Glasgow Coma Scale (GCS) 13 or greater~* Hunt and Hess grade I, II conditions~* Admitted within 2 days of initial SAH event \>6/10 pain on presentation~Exclusion Criteria:~* Aphasia~* Head trauma within the past 30 days~* Need for craniotomy~* h/o obstructive sleep apnea or respiratory disease~* h/o opioid tolerance~* evidence of vasospasm~* h/o liver disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Control group / Standard of Care (Type: ACTIVE_COMPARATOR): * IV fentanyl bolus 25-50 mcg every 1-2 hrs as needed for pain~* (Bolus dose can be titrated up in 25 mcg increments if necessary)~* Maximum dose of 100 mcg/hr
- Low dose IV fentanyl PCA (Type: ACTIVE_COMPARATOR): * Initially: 10 mcg demand dose every 12 minutes~* No initial bolus and no continuous infusion~* Demand dose increased 10 mcg every 12 minutes if necessary~* Maximum dose of 100 mcg/hr

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues